La importancia de Orphan Drug Designation (ODD) y sus 7 años de monopolio una vez conseguido el FDA Approved. ( Exepto claro en KV-A que termino en la bancarrrota por la pesima gestion de su direccion)
-->
http://orphandruganaut.wordpress.com/2014/01/20/aegerion-pharmaceuticals-juxtapid-sales-continue-to-climb/
Aegerion Pharmaceuticals, Inc. (Public, NASDAQ:AEGR) Watch this stock
62.51 +2.52 (4.20%)
For 2013, $48 – $49 million in Preliminary (Unaudited) Net Product Sales (reference graph in presentation):
$ 1.2 million in Q1 2013
$ 6.5 million in Q2 2013
$16.3 million in Q3 2013
Estimation of $25 million in Q4 2013
• For 2014, Revenue Guidance of $190 – $210 million in Net Product Sales
• 100% of Juxtapid prescriptions process from REMS certified physicians
• HoFH prevalence is underestimated; less than 1% currently diagnosed
• Will continue the growth of Juxtapid in the US for 2014, by more effective patient onboarding and support